The problem of antibacterial resistance to frequently used antibiotics has led to a search for newer and alternative compounds for the treatment of drugresistant infections [1]. Although pharmaceutical companies have designed a number of new antibiotics in the last three decades, resistance against these drugs by microorganisms has also been observed. Drug resistant bacterial infections are causing immense mortality and morbidity worldwide. For example, in 2005, in the United States, 19 000 out of 95 000 patients affected from methicillin-resistant Staphylococcus aureus (MRSA) have died. Number of death was higher than number of deaths combined from HIV/ AIDS, Parkinson's disease, emphysema, and homicides combined [2]. As many branches of treatments like postsurgical care, neonatal care, transplantation medicine, cancer chemotherapy, and care of the critically ill patients need effective antibiotic treatment, failure of conventional antibiotic treatment to combat multidrug resistant (MDR) pathogens, caused high rate of mortality. With this background, World Health Organization (WHO) identified MDR bacteria as one of the top three high priority threats to human health. Infectious Disease Society of America has addressed the biomedical community to declare a war against the MDR bacterial threat. Along with intensifying research on understanding the resistance pattern of MDR infection, they have stressed that the ultimate goal of scientist would be to identify appropriate and efficient antimicrobial drugs to the patients.